Harbour BioMed nets $75M in Series B+ as first global trial gets underway

Harbour BioMed nets $75M in Series B+ as first global trial gets underway

Source: 
Endpoints
snippet: 

Nearly two years after drawing an $85 million Series B, Shanghai-based Harbour BioMed has announced a new large funding round.